Skip to main content
Log in

Histologie und Molekularpathologie von Speicheldrüsentumoren

Histology and molecular pathology of salivary gland tumors

  • Leitthema
  • Published:
Der MKG-Chirurg Aims and scope

Zusammenfassung

Hintergrund

Speicheldrüsentumoren sind zwar sehr selten, zeigen aber eine große morphologische Heterogenität mit über 30 verschiedenen Entitäten. In jüngster Zeit ließen sich die verschiedenen Tumoren nicht nur histologisch und immunhistochemisch, sondern auch molekular besser als zuvor charakterisieren, sodass zunehmend sog. Treibermutationen, die eine Rolle bei der Entwicklung neuer, auf eine Zielstruktur gerichteter Therapien spielen, entdeckt wurden.

Ziel

Ziel des Beitrags ist es, grundlegende morphologische und immunhistochemische Parameter zur Differenzierung einzelner Tumorentitäten vorzustellen sowie einen Überblick über die bislang gefundenen genetischen Aberrationen der häufigsten Speicheldrüsentumoren zu geben.

Material und Methoden

Fälle aus dem eigenen Einsendegut mit histochemischen Standard- und immunhistochemischen Sonderfärbungen werden präsentiert. Daneben bildet eine umfassende Literaturrecherche den derzeitigen Kenntnisstand über molekulare Veränderungen in Speicheldrüsentumoren ab.

Ergebnisse und Schlussfolgerung

In der histopathologischen Diagnostik differenzierter Speicheldrüsentumoren ist die immunhistochemische Markierung basaler/myoepithelialer und luminaler/epithelialer Zellen zur Beurteilung von Komposition und Architektur verschiedener Zelltypen neben der Bestimmung der proliferativen Aktivität essenziell. Auf Basis einer korrekten Tumortypisierung können verschiedene molekulare Parameter untersucht werden, um im Falle hoch differenzierter nichtmetastasierter Tumoren die Diagnose weiter zu verifizieren und im Falle gering differenzierter, metastasierter Tumoren mögliche therapeutische Zielstrukturen zu identifizieren. Bei hochaggressiven Karzinomen erscheint nach heutigem Kenntnisstand die Erstellung eines umfassenden genomischen Profils wesentlich.

Abstract

Background

Salivary gland tumors are rare but display great morphological heterogeneity with more than 30 entities. Recently, the different tumors have not only been better characterized using conventional histochemical and immunohistochemical methods, but also by molecular means. Hence, so-called driver mutations which play a role in the development of novel molecularly targeted therapies could be identified.

Objective

The article aims to show morphological criteria and immunohistochemical characteristics of different tumor entities. Additionally, an overview of tumor-specific genetic aberrations of the most common salivary gland tumors is given.

Materials and methods

Samples from daily routine practice are presented with histochemical and immunohistochemical staining. To compile recent molecular findings in salivary gland tumors, a literature review was performed.

Results and conclusion

For histopathological diagnosis of differentiated salivary gland tumors, immunohistochemical staining of basal/myoepithelial and luminal/epithelial cells is essential to assess cellular architecture and attribute proliferative activity. Based on correct tumor typing, various molecular parameters can be investigated in order to verify the diagnosis of highly differentiated nonmetastatic tumors. In the case of less differentiated, metastatic cancers, molecular pathology permits identification of potential therapeutic targets. Comprehensive genome profiling should nowadays be applied to highly aggressive salivary gland cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Carvalho AL, Nishimoto IN, Califano JA et al (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114:806–816

    Article  CAS  Google Scholar 

  2. Jo VY, Krane JF (2018) Ancillary testing in salivary gland cytology: a practical guide. Cancer Cytopathol 126(8):627–642

    Article  Google Scholar 

  3. Di Villeneuve L, Souza IL, Tolentino FDS et al (2021) Corrigendum: salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 11:669486

    Article  Google Scholar 

  4. Di Villeneuve L, Souza IL, Tolentino FDS et al (2020) Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 10:580141

    Article  Google Scholar 

  5. Griffith CC, Schmitt AC, Little JL et al (2017) New developments in salivary gland pathology: clinically useful ancillary testing and new potentially targetable molecular alterations. Arch Pathol Lab Med 141:381–395

    Article  Google Scholar 

  6. Ha PK, Stenman G (2016) Molecular pathology and biomarkers. Adv Otorhinolaryngol 78:17–24

    PubMed  PubMed Central  Google Scholar 

  7. Haller F, Bieg M, Will R et al (2019) Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. Nat Commun 10:368

    Article  CAS  Google Scholar 

  8. Sentani K, Ogawa I, Ozasa K et al (2019) Characteristics of 5015 salivary gland neoplasms registered in the Hiroshima tumor tissue registry over a period of 39 years. J Clin Med 8(5):566. https://doi.org/10.3390/jcm8050566

    Article  PubMed Central  Google Scholar 

  9. Mark J, Dahlenfors R, Ekedahl C et al (1982) Chromosomal patterns in a benign human neoplasm, the mixed salivary gland tumour. Hereditas 96:141–148

    Article  CAS  Google Scholar 

  10. Stenman G (2013) Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 7(1):S12–19

    Article  Google Scholar 

  11. Tessari MA, Gostissa M, Altamura S et al (2003) Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 23:9104–9116

    Article  CAS  Google Scholar 

  12. Schwarz S, Stiegler C, Muller M et al (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58:557–570

    Article  Google Scholar 

  13. Auclair PL, Goode RK, Ellis GL (1992) Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer 69:2021–2030

    Article  CAS  Google Scholar 

  14. Brandwein MS, Ivanov K, Wallace DI et al (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25:835–845

    Article  CAS  Google Scholar 

  15. Okumura Y, Nakano S, Murase T et al (2020) Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: a multiinstitutional retrospective study. Cancer Sci 111:4195–4204

    Article  CAS  Google Scholar 

  16. Chen Z, Chen J, Gu Y et al (2014) Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells. Oncogene 33:3869–3877

    Article  CAS  Google Scholar 

  17. Norberg-Spaak L, Dardick I, Ledin T (2000) Adenoid cystic carcinoma: use of cell proliferation, BCL‑2 expression, histologic grade, and clinical stage as predictors of clinical outcome. Head Neck 22:489–497

    Article  CAS  Google Scholar 

  18. Higashi K, Jin Y, Johansson M et al (1991) Rearrangement of 9p13 as the primary chromosomal aberration in adenoid cystic carcinoma of the respiratory tract. Genes Chromosomes Cancer 3:21–23

    Article  CAS  Google Scholar 

  19. Stenman G, Andersson MK, Andren Y (2010) New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle 9:2986–2995

    Article  CAS  Google Scholar 

  20. Stephens PJ, Davies HR, Mitani Y et al (2013) Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 123:2965–2968

    Article  CAS  Google Scholar 

  21. Ross JS, Wang K, Rand JV et al (2014) Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. Am J Surg Pathol 38:235–238

    Article  Google Scholar 

  22. Schwarz S, Muller M, Ettl T et al (2011) Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Int J Clin Exp Pathol 4:336–348

    PubMed  PubMed Central  Google Scholar 

  23. Weinreb I, Piscuoglio S, Martelotto LG et al (2014) Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet 46:1166–1169

    Article  CAS  Google Scholar 

  24. Weinreb I, Zhang L, Tirunagari LM et al (2014) Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer 53:845–856

    Article  CAS  Google Scholar 

  25. Schwarz S, Zenk J, Muller M et al (2012) The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology 61:395–408

    Article  Google Scholar 

  26. Barasch N, Gong X, Kwei KA et al (2017) Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma. PLoS ONE 12:e171265

    Article  Google Scholar 

  27. Skalova A, Vanecek T, Sima R et al (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34:599–608

    Article  Google Scholar 

  28. Chiosea SI, Griffith C, Assaad A et al (2012) Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology 61:387–394

    Article  Google Scholar 

  29. Dalin MG, Desrichard A, Katabi N et al (2016) Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res 22:4623–4633

    Article  CAS  Google Scholar 

  30. Gargano SM, Senarathne W, Feldman R et al (2019) Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med 8:7322–7329

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephan Schwarz-Furlan.

Ethics declarations

Interessenkonflikt

S. Schwarz-Furlan gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Benedicta Beck-Broichsitter, Berlin

Tobias Ettl, Regensburg

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schwarz-Furlan, S. Histologie und Molekularpathologie von Speicheldrüsentumoren. MKG-Chirurg 14, 287–295 (2021). https://doi.org/10.1007/s12285-021-00324-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12285-021-00324-3

Schlüsselwörter

Keywords

Navigation